Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CERo Therapeutics Holdings ( (CERO) ) has shared an update.
On December 19, 2025, CERo Therapeutics Holdings, Inc. held a Special Meeting of Stockholders at which shareholders approved an amendment to the company’s 2024 Equity Incentive Plan to add 32,000,000 additional shares of common stock available for issuance, significantly expanding the pool for equity-based compensation. At the same meeting, stockholders also approved a charter amendment authorizing a reverse stock split at a ratio between 1-for-40 and 1-for-150 at the board’s discretion, and approved, subject to conditions, the issuance of common shares upon conversion of Series E convertible preferred stock issued in an October 2025 private placement, decisions that collectively position the company to better manage its capital structure, maintain listing compliance, and enhance its flexibility in financing and incentivizing key personnel, although they also imply potential future dilution for existing shareholders.
The most recent analyst rating on (CERO) stock is a Hold with a $0.10 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. is a biotechnology company focused on developing therapeutic products, operating in the life sciences sector and accessing public equity markets to support its growth and compensation programs for employees and executives.
Average Trading Volume: 1,831,002
Technical Sentiment Signal: Sell
Current Market Cap: $1.79M
Learn more about CERO stock on TipRanks’ Stock Analysis page.